Randomised controlled trialindependent cross-checkabstract only checked★ key study I-BAR-02 in-depth review

Diabetes 12 years after randomized surgery vs medicine

Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes.

Overview

Courcoulas AP et al.. JAMA 2024 · PMID 38411644 · DOI 10.1001/jama.2024.0318

Blood sugar control stayed better after surgery; full remission was uncommon in both groups but more frequent after surgery (12.7% vs 0%).

Does the study support the specific claim? Partly · Methodological quality: moderate

Study explained simply

What did the researchers want to find out?: Long-term T2D
How was the study done?: Pooled RCT follow-up
How many people, animals or samples were studied?: 262
What was actually found?: Surgery better; remission declines
How large was the observed effect?: HbA1c -1.1% at 12 y
What do the results mean in everyday life?: Relapse is common, but surgery keeps an advantage
What are the study's limitations?: Crossover, small
What does it say about Elawady's specific claim?: Partly supports erosion; contradicts 'no benefit'
Do the results apply to Germany and Europe?: Applicable
What can explicitly not be concluded from this study?: Mortality

Authors: Courcoulas AP et al.
Journal: JAMA
Year: 2024
Identifier: PMID 38411644 DOI 10.1001/jama.2024.0318
Verification: verified – PubMed efetch 2026-10-25
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: NIDDK/NIGMS grants; COI not in PubMed record.

Long-term glycemic control after surgery vs medical/lifestyle management

Study design: Randomised controlled trial – Pooled long-term follow-up of 4 US single-centre RCTs (ARMMS-T2D)
Population: T2D, mean BMI 36.4
Country: USA
Period: 2007-2022
Sample size: 262 of 305 eligible

Results: HbA1c difference -1.4% (-1.8 to -1.0) at 7 y and -1.1% at 12 y. Remission 18.2% vs 6.2% at 7 y; 12.7% vs 0.0% at 12 y. Deaths 2 vs 2. Anemia, fractures and GI adverse events more common after surgery. 25% of medical group crossed over to surgery.
Absolute risks: Remission 12.7% vs 0% at 12 years
Authors' conclusion: Superior glycemic control, less medication, higher remission after surgery at 7-12 years.

Shows both diabetes relapse (low long-term remission) and persistent superiority; also documents more fractures and anemia.

US data; consistent with European RCT (Mingrone).

Best long-term randomized evidence; supports both 'remission erodes' and 'surgery still better'.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	moderate
Risk of bias	some concerns
Precision of results	moderate
Directness	direct
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	moderate
Adequacy of the interpretation (by the archive)	not applicable